Antibiotic Development To Get Fresh Push, Not Fresh Ideas, From PCAST
This article was originally published in The Pink Sheet Daily
Upcoming report from presidential advisors will endorse limited population approval, and government funding mechanisms as part of plan to fight resistance.
You may also be interested in...
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.